166 related articles for article (PubMed ID: 16949503)
21. Letter 2: meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335-1344).
Tangelder MJ; Bylock A; Held P
Br J Surg; 2006 Mar; 93(3):374-5; author reply 375-6. PubMed ID: 16498578
[No Abstract] [Full Text] [Related]
22. Direct thrombin inhibition: a novel approach to stroke prevention in patients with atrial fibrillation.
Elkind MS; Sacco RL
Stroke; 2004 Jun; 35(6):1519-22. PubMed ID: 15143301
[No Abstract] [Full Text] [Related]
23. [Ximelagatran].
Nagata K
Nihon Rinsho; 2006 Oct; 64 Suppl 7():630-6. PubMed ID: 17461216
[No Abstract] [Full Text] [Related]
24. Aspirin bias in SPORTIF III trial.
Vadivelu MK
Lancet; 2004 Jun; 363(9426):2091; author reply 2091. PubMed ID: 15207972
[No Abstract] [Full Text] [Related]
25. Can we pull the plug on warfarin in atrial fibrillation?
Verheugt FW
Lancet; 2003 Nov; 362(9397):1686-7. PubMed ID: 14643112
[No Abstract] [Full Text] [Related]
26. Potential effect of ximelagatran use on an anticoagulation clinic.
Burkiewicz JS
Am J Health Syst Pharm; 2004 Dec; 61(23):2490, 2492. PubMed ID: 15595221
[No Abstract] [Full Text] [Related]
27. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials.
Kaul S; Diamond GA
Prog Cardiovasc Dis; 2007; 49(4):284-99. PubMed ID: 17185116
[TBL] [Abstract][Full Text] [Related]
28. Ximelagatran for secondary prevention of venous thromboembolism.
Böger C; Schroll S; Holmer S
N Engl J Med; 2004 Feb; 350(6):618-9; author reply 618-9. PubMed ID: 14768068
[No Abstract] [Full Text] [Related]
29. Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety.
Kamali F; Wood P; Ward A
Ann Hematol; 2009 Feb; 88(2):141-9. PubMed ID: 18716776
[TBL] [Abstract][Full Text] [Related]
30. Ximelagatran for secondary prevention of venous thromboembolism.
Vaknansky A; Kupfer Y; Tessler S
N Engl J Med; 2004 Feb; 350(6):618-9; author reply 618-9. PubMed ID: 14762193
[No Abstract] [Full Text] [Related]
31. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
Harenberg J; Jörg I; Weiss C
Int J Toxicol; 2006; 25(3):165-9. PubMed ID: 16717032
[TBL] [Abstract][Full Text] [Related]
32. Ximelagatran in the clinic: practical management of patients.
Schulman S; Lip GY
Semin Vasc Med; 2005 Aug; 5(3):301-7. PubMed ID: 16123918
[TBL] [Abstract][Full Text] [Related]
33. Testing an alternative to warfarin.
Harv Heart Lett; 2004 Feb; 14(6):7. PubMed ID: 14980888
[No Abstract] [Full Text] [Related]
34. Anticoagulants. Oral drug options may expand.
Mayo Clin Health Lett; 2004 Jun; 22(6):6. PubMed ID: 15199917
[No Abstract] [Full Text] [Related]
35. [Ximelagatran (Exanta). Laboratory: Astra Zeneca].
Moreno Alvarez PJ
Farm Hosp; 2004; 28(2):146-8. PubMed ID: 15154414
[No Abstract] [Full Text] [Related]
36. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data.
Gjesdal K; Feyzi J; Olsson SB
Heart; 2008 Feb; 94(2):191-6. PubMed ID: 17483128
[TBL] [Abstract][Full Text] [Related]
37. Preface. Ximelagatran and oral direct thrombin inhibition.
McCullough PA
Rev Cardiovasc Med; 2004; 5 Suppl 5():S1. PubMed ID: 15619609
[No Abstract] [Full Text] [Related]
38. An orwellian discourse on the meaning and measurement of noninferiority.
Diamond GA; Kaul S
Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435
[TBL] [Abstract][Full Text] [Related]
39. Effect of hypertension on anticoagulated patients with atrial fibrillation.
Lip GY; Frison L; Grind M;
Eur Heart J; 2007 Mar; 28(6):752-9. PubMed ID: 17289744
[TBL] [Abstract][Full Text] [Related]
40. Ximelagatran: an eulogy.
Boos CJ; Lip GY
Thromb Res; 2006; 118(3):301-4. PubMed ID: 16626788
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
